Abstract Long-term survival of patients with histologically confirmed glioblastoma is a rare event with figures in the range of 2-3% for 5-year survival (Scott et al.
It has been suggested that glioblastoma is not the leading cause of death in patients that have survived for more than 10 years after diagnosis [4] . We have previously reported a comprehensive analysis of the clinical outcome of 10 patients who had survived 5 years from the diagnosis of glioblastoma confirmed by neuropathological reassessment with a mean follow-up of 93.2 months (range, 60-120 months) [5] . At that time, one patient had died 69 months after diagnosis, one other patient was receiving treatment for recurrent disease 106 months after diagnosis, while eight patients were free of recurrence 60-120 months after diagnosis. Notably, among these ten patients, who had completed primary therapy, no recurrences had occurred later than 3 years after diagnosis. Therefore, the possibility of a definite cure for some of these patients who were free of progression for almost 10 years was entertained. In support of this, a previous study suggested that death from recurrent glioblastoma was unusual in patients who had survived for more than 5 years [4] . Here, we briefly report a further survival analysis of our cohort after a mean follow-up of 139.4 months (range 102-164 months). This cohort consisted of younger than average patients in predominantly excellent clinical condition. Gross total resections had been achieved in all but one of the 10 patients. All patients had received radiotherapy and adjuvant nitrosourea-based chemotherapy. A total of four patients of the nine patients alive at the previous analysis have died during the extended follow-up. Three of these patients died from recurrent tumor. One patient (no. 4) died from leukoencephalopathy-associated complications without evidence of tumor progression and one patient (no. 5) was already deceased at the time of our previous analysis. Details concerning the occurrence of relapses and their treatment are displayed in Table 1 . Individual progression-free survival curves are shown in Fig. 1 . Notably, very late relapses occurred in three patients after 118, 124 and 126 months of progression-free survival. Thus, from the original cohort of 10 patients only 3 remain free from recurrence after the extended follow-up of more than 10 years (123, 134 and 145 months for patients 8, 7 and 1, respectively). These patients have done very well, however. Patient one from the original series, a farmer, still maintains his small farm and serves on the council of the local town. He has mild impairment of emotional control but no focal deficits. Patient seven has given birth to two healthy children 52 and 84 months from the diagnosis of glioblastoma and continues to work parttime. She has suffered from repetitive vestibular and cochlear injury on the tumor side, possibly as a consequence of radiation injury and is otherwise unremarkable. Patient eight has also given birth to a healthy child 67 months from the diagnosis of glioblastoma and continues to work part-time. She suffers from incomplete hemianopia since surgery. The remaining patient has been diagnosed with tumor recurrence and is currently awaiting surgery. She has good cognitive function, but is wheelchair bound due to postoperative hemiparesis. In summary, the extended follow-up of glioblastoma long-term survivors reveals that excellent clinical courses beyond 10 years after the diagnosis are possible, but also cautions that the risk of tumor recurrence remains high. Thus, it appears While the current routine at most institutions is to extend the control intervals to 6 months and 1 year after 2 and 5 years of survival, respectively, our results challenge this procedure. Though it remains unproven that earlier diagnosis of recurrence will result in better chances to achieve tumor control, the case histories of some of our patients are suggestive of such a benefit. In patients 3, 4, 5, and 6 recurrences without clinical symptoms were detected by imaging, and a gross total resection was achieved in all of them. In patient 10, a seizure heralded recurrence although the patient had no longer been in routine followup, and a gross total resection was also achieved. Patient 9, however, had refused further imaging and after 124 months was admitted for progressive personality change and hemiparesis on the left side. MR imaging revealed a large recurrent tumor in the right frontal lobe with extension into the basal ganglia. Only a decompressive partial resection was feasible, and the patient died 3 months after the diagnosis of recurrence.
In conclusion, very late relapses pose a serious threat for glioblastoma long-term survivors and call for continuous vigilance. The maintenance of a tight control schedule even in a patient surviving for more than 10 years should be considered.
